Hallucinogens, serotonin and obsessive-compulsive disorder

Pedro L. Delgado, Francisco Moreno

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The serotonin (5-HT) neurotransmitter system has been implicated in the pathophysiology of several neuropsychiatric disorders, especially obsessive-compulsive disorder (OCD). Blockade of 5-HT reuptake appears to be an important initial neurobiological event in the therapeutic mechanism of action of antiobsessional drugs. However, for reasons that continue to be poorly understood, clinical improvement following initiation of treatment with 5-HT reuptake inhibitors can take up to eight to 12 weeks, and most patients do not fully improve. Recent data suggest that activation of 5-HT2A and/or 5-HT2C receptors may be important for the improvement of OCD symptoms. Most psychedelic drugs are potent agonists at 5-HT2A and 5-HT2C receptors and their binding potency to these receptors is strongly correlated with their human potency as hallucinogens. This article will briefly review the relevant clinical and preclinical studies relating to the effects of hallucinogens on OCD. These data suggest that activation of 5-HT2 receptors by hallucinogens may lead to acute reduction of, as well as possible longer-lasting beneficial effects on, the symptoms of OCD. Evidence for and against involvement of 5-HT2A and/or 5-HT2C receptors in the therapeutic effects of drug therapies for OCD are rev iewed. Issues related to the pharmacological properties and safety of psychedelic drugs, when considered as potential treatments for patients with OCD, are summarized. The authors suggest that controlled trials of potent 5-HT2 agonists in people suffering from OCD are warranted.

Original languageEnglish (US)
Pages (from-to)359-366
Number of pages8
JournalJournal of Psychoactive Drugs
Volume30
Issue number4
DOIs
StatePublished - 1998

Fingerprint

Hallucinogens
Obsessive-Compulsive Disorder
Serotonin
Receptor, Serotonin, 5-HT2C
Serotonin 5-HT2 Receptor Agonists
Pharmaceutical Preparations
Therapeutic Uses
Neurotransmitter Agents
Therapeutics
Pharmacology
Safety
Drug Therapy

Keywords

  • Adverse effects
  • Antidepressant
  • Anxiety disorder
  • Serotonin receptors
  • Serotonin reuptake inhibitor

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Psychology(all)

Cite this

Hallucinogens, serotonin and obsessive-compulsive disorder. / Delgado, Pedro L.; Moreno, Francisco.

In: Journal of Psychoactive Drugs, Vol. 30, No. 4, 1998, p. 359-366.

Research output: Contribution to journalArticle

@article{83a8001d96a54dd18e88111f9e8f9022,
title = "Hallucinogens, serotonin and obsessive-compulsive disorder",
abstract = "The serotonin (5-HT) neurotransmitter system has been implicated in the pathophysiology of several neuropsychiatric disorders, especially obsessive-compulsive disorder (OCD). Blockade of 5-HT reuptake appears to be an important initial neurobiological event in the therapeutic mechanism of action of antiobsessional drugs. However, for reasons that continue to be poorly understood, clinical improvement following initiation of treatment with 5-HT reuptake inhibitors can take up to eight to 12 weeks, and most patients do not fully improve. Recent data suggest that activation of 5-HT2A and/or 5-HT2C receptors may be important for the improvement of OCD symptoms. Most psychedelic drugs are potent agonists at 5-HT2A and 5-HT2C receptors and their binding potency to these receptors is strongly correlated with their human potency as hallucinogens. This article will briefly review the relevant clinical and preclinical studies relating to the effects of hallucinogens on OCD. These data suggest that activation of 5-HT2 receptors by hallucinogens may lead to acute reduction of, as well as possible longer-lasting beneficial effects on, the symptoms of OCD. Evidence for and against involvement of 5-HT2A and/or 5-HT2C receptors in the therapeutic effects of drug therapies for OCD are rev iewed. Issues related to the pharmacological properties and safety of psychedelic drugs, when considered as potential treatments for patients with OCD, are summarized. The authors suggest that controlled trials of potent 5-HT2 agonists in people suffering from OCD are warranted.",
keywords = "Adverse effects, Antidepressant, Anxiety disorder, Serotonin receptors, Serotonin reuptake inhibitor",
author = "Delgado, {Pedro L.} and Francisco Moreno",
year = "1998",
doi = "10.1080/02791072.1998.10399711",
language = "English (US)",
volume = "30",
pages = "359--366",
journal = "Journal of Psychoactive Drugs",
issn = "0279-1072",
publisher = "Haight-Ashbury Publications",
number = "4",

}

TY - JOUR

T1 - Hallucinogens, serotonin and obsessive-compulsive disorder

AU - Delgado, Pedro L.

AU - Moreno, Francisco

PY - 1998

Y1 - 1998

N2 - The serotonin (5-HT) neurotransmitter system has been implicated in the pathophysiology of several neuropsychiatric disorders, especially obsessive-compulsive disorder (OCD). Blockade of 5-HT reuptake appears to be an important initial neurobiological event in the therapeutic mechanism of action of antiobsessional drugs. However, for reasons that continue to be poorly understood, clinical improvement following initiation of treatment with 5-HT reuptake inhibitors can take up to eight to 12 weeks, and most patients do not fully improve. Recent data suggest that activation of 5-HT2A and/or 5-HT2C receptors may be important for the improvement of OCD symptoms. Most psychedelic drugs are potent agonists at 5-HT2A and 5-HT2C receptors and their binding potency to these receptors is strongly correlated with their human potency as hallucinogens. This article will briefly review the relevant clinical and preclinical studies relating to the effects of hallucinogens on OCD. These data suggest that activation of 5-HT2 receptors by hallucinogens may lead to acute reduction of, as well as possible longer-lasting beneficial effects on, the symptoms of OCD. Evidence for and against involvement of 5-HT2A and/or 5-HT2C receptors in the therapeutic effects of drug therapies for OCD are rev iewed. Issues related to the pharmacological properties and safety of psychedelic drugs, when considered as potential treatments for patients with OCD, are summarized. The authors suggest that controlled trials of potent 5-HT2 agonists in people suffering from OCD are warranted.

AB - The serotonin (5-HT) neurotransmitter system has been implicated in the pathophysiology of several neuropsychiatric disorders, especially obsessive-compulsive disorder (OCD). Blockade of 5-HT reuptake appears to be an important initial neurobiological event in the therapeutic mechanism of action of antiobsessional drugs. However, for reasons that continue to be poorly understood, clinical improvement following initiation of treatment with 5-HT reuptake inhibitors can take up to eight to 12 weeks, and most patients do not fully improve. Recent data suggest that activation of 5-HT2A and/or 5-HT2C receptors may be important for the improvement of OCD symptoms. Most psychedelic drugs are potent agonists at 5-HT2A and 5-HT2C receptors and their binding potency to these receptors is strongly correlated with their human potency as hallucinogens. This article will briefly review the relevant clinical and preclinical studies relating to the effects of hallucinogens on OCD. These data suggest that activation of 5-HT2 receptors by hallucinogens may lead to acute reduction of, as well as possible longer-lasting beneficial effects on, the symptoms of OCD. Evidence for and against involvement of 5-HT2A and/or 5-HT2C receptors in the therapeutic effects of drug therapies for OCD are rev iewed. Issues related to the pharmacological properties and safety of psychedelic drugs, when considered as potential treatments for patients with OCD, are summarized. The authors suggest that controlled trials of potent 5-HT2 agonists in people suffering from OCD are warranted.

KW - Adverse effects

KW - Antidepressant

KW - Anxiety disorder

KW - Serotonin receptors

KW - Serotonin reuptake inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0032428621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032428621&partnerID=8YFLogxK

U2 - 10.1080/02791072.1998.10399711

DO - 10.1080/02791072.1998.10399711

M3 - Article

VL - 30

SP - 359

EP - 366

JO - Journal of Psychoactive Drugs

JF - Journal of Psychoactive Drugs

SN - 0279-1072

IS - 4

ER -